Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors

Maya S. Safarova, Iftikhar J. Kullo

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)30-31
Number of pages2
JournalAtherosclerosis
Volume361
DOIs
StatePublished - Nov 2022

Keywords

  • ASCVD
  • LDL
  • Lipoprotein(a)
  • Mendelian randomization
  • PCSK9 inhibitors
  • Residual risk

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this